COPROMOTION AGREEMENT By and between IMPAX LABORATORIES, INC. and WYETH acting through its WYETH PHARMACEUTICALS DIVISION July 16, 2008Copromotion Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations
This Copromotion Agreement (the “Agreement”) is made and entered into as of July 16, 2008 (the “Effective Date”), by and between Wyeth, acting through its Wyeth Pharmaceuticals Division, having a place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426 (“Wyeth”) and Impax Laboratories, Inc., having a place of business at 30831 Huntwood Avenue, Hayward, California 94544 (“Impax”). Wyeth and Impax may each be referred to herein individually as a “Party” and collectively as the “Parties.”
SUBLICENSE AGREEMENTSublicense Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations
This Sublicense Agreement (the “Agreement”), effective as of March 30, 2007 (the “Effective Date”), is by and between DAVA Pharmaceuticals, Inc., a Delaware corporation (“DAVA”), and IMPAX Laboratories, Inc., a Delaware corporation (“IMPAX”).
ContractSupplemental License Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations • New York
ContractPatent License Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations • New York
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT dated as of June 18, 2002 between WYETH acting through its Wyeth Consumer Healthcare Division and IMPAX LABORATORIES, INC. for Loratadine/Pseudoephedrine Combination TabletsDevelopment, License and Supply Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT is made and entered into as of this 1st day of June 2002, between WYETH, a corporation organized and existing under the laws of Delaware, acting through its Wyeth Consumer Healthcare Division and having an address at Five Giralda Farms, Madison, New Jersey 07940 (“WCH”) and IMPAX LABORATORIES, INC., a corporation organized and existing under the laws of Delaware and having an address at 3735 Castor Avenue, Philadelphia, Pennsylvania 19124 (“IMPAX”).
ContractLicensing, Contract Manufacturing and Supply Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations
ContractStrategic Alliance Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations
ContractLicensing, Contract Manufacturing and Supply Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations
LICENSING, CONTRACT MANUFACTURING & SUPPLY AGREEMENT between SCHERING CORPORATION and IMPAX LABORATORIES, INC.Licensing, Contract Manufacturing & Supply Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations • New Jersey
THIS AGREEMENT, effective as of the last date of signature appearing below (the “Effective Date”), is entered into by and between Schering Corporation, a corporation organized under the laws of New Jersey, with its principal office at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (hereafter called “Schering”), and Impax Laboratories, Inc., a corporation organized under the laws of Delaware, with its principal offices at 30831 Huntwood Avenue, Hayward, California 94550 (hereafter called “Impax”).
ContractStrategic Alliance Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations
AMENDMENT TO THE DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT BETWEEN WYETH, ACTING THROUGH ITS WYETH CONSUMER HEALTHCARE DIVISION, AND IMPAX LABORATORIES, INC.Development, License and Supply Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations
This Amendment, effective as of the last date of signature appearing below (the “Effective Date”), to the Development, License and Supply Agreement, dated as of June 1, 2002 and amended by letters dated November 19, 2002, April 23, 2003 and May 15, 2003, for Loratadine/Pseudoephedrine Combination Tablets (the “Agreement”) is entered into by and between Wyeth, acting through its Wyeth Consumer Healthcare Division (hereinafter called “WCH”), and Impax Laboratories, Inc. (hereinafter called “Impax”).
ContractSupply and Distribution Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations • Delaware
PROMOTIONAL SERVICES AGREEMENTPromotional Services Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations • Pennsylvania
NOW, THEREFORE, in consideration of the mutual covenants set out in this Agreement, and intending to be legally bound hereby, the Parties agree as follows.
STRATEGIC ALLIANCE AGREEMENT between TEVA PHARMACEUTICALS CURACAO N.V. World Trade Center Curacao, Unit T.M.I. 14, Piscadera Bay Curacao, Netherlands Antilles (“Teva”) and IMPAX LABORATORIES, INC. a corporation organized under the laws of Delaware,...Strategic Alliance Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations • Pennsylvania
WHEREAS, Impax is engaged in the development, manufacture, sale, marketing and distribution of pharmaceutical products and has in various stages of development the pharmaceutical products listed in Annex A hereto (collectively the “Products” as defined further below);
SUPPLY AND DISTRIBUTION AGREEMENT BETWEEN IMPAX LABORATORIES, INC. AND DAVA PHARMACEUTICALS, INC. DATED AS OF NOVEMBER 3, 2005Supply and Distribution Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations • Delaware
This Supply Agreement (“Agreement”) is dated as of the 3rd day of November, 2005 by and between DAVA Pharmaceuticals, Inc., a Delaware corporation (hereinafter referred to as “DAVA”), with offices located at 400 Kelby Street, 10th Floor, Fort Lee, NJ 07024, and IMPAX Laboratories, Inc., a Delaware corporation (hereinafter referred to as “IMPAX”), with headquarters located at 30831 Huntwood Avenue, Hayward, CA 94544.
AMENDMENT TO STRATEGIC ALLIANCE AGREEMENTStrategic Alliance Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations
This AMENDMENT dated as of January 24, 2006 (the “Amendment”) to the Strategic Alliance Agreement dated as of June 27, 2001, as amended to date , by and between TEVA PHARMACEUTICALS CURACAO N.V., a Netherlands Antilles company (“Teva”), and IMPAX LABORATORIES, INC., a Delaware corporation (“Impax”), (the “Strategic Alliance Agreement”). All capitalized terms used herein, unless otherwise defined herein, shall have the respective meanings set forth in the Strategic Alliance Agreement.
AMENDMENT TO THE DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT BETWEEN WYETH, ACTING THROUGH ITS WYETH CONSUMER HEALTHCARE DIVISION, AND IMPAX LABORATORIES, INC.Development, License and Supply Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations
This Amendment, effective as of February 14, 2005 (the “Effective Date”), to the Development, License and Supply Agreement, dated as of June 1, 2002 and amended by letters dated November 19, 2002, April 23, 2003 and May 15, 2003 and amendment dated July 9, 2004, for Loratadine/Pseudoephedrine Combination Tablets (the “Agreement”) is entered into by and between Wyeth, acting through its Wyeth Consumer Healthcare Division (hereinafter called “WCH”), and Impax Laboratories, Inc. (hereinafter called “IMPAX”).
